Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:ASNDNASDAQ:BBIONASDAQ:IONSNASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$20.88-0.3%$20.39$13.40▼$25.23$3.51B0.641.98 million shs2.02 million shsASNDAscendis Pharma A/S$175.98+1.0%$167.90$111.09▼$183.00$10.65B0.38501,562 shs476,887 shsBBIOBridgeBio Pharma$43.50-1.1%$38.08$21.72▼$45.48$8.35B1.152.51 million shs2.54 million shsIONSIonis Pharmaceuticals$41.78-2.8%$35.48$23.95▼$52.34$6.84B0.231.61 million shs2.24 million shsRAREUltragenyx Pharmaceutical$39.61-0.8%$36.75$29.59▼$60.37$3.77B0.26840,199 shs1.10 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.33%-3.20%-5.00%+48.09%+29.45%ASNDAscendis Pharma A/S+1.10%+1.96%+1.69%+28.07%+29.58%BBIOBridgeBio Pharma-0.47%+0.74%+12.64%+44.33%+68.87%IONSIonis Pharmaceuticals-2.79%+5.75%+18.39%+63.78%-9.35%RAREUltragenyx Pharmaceutical+1.07%+8.94%+6.56%+27.53%-3.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals4.6784 of 5 stars4.43.00.00.03.24.22.5ASNDAscendis Pharma A/S3.5704 of 5 stars4.53.00.00.02.51.70.6BBIOBridgeBio Pharma4.6716 of 5 stars4.52.00.03.92.33.30.6IONSIonis Pharmaceuticals4.6576 of 5 stars4.42.00.03.03.33.30.6RAREUltragenyx Pharmaceutical3.935 of 5 stars3.51.00.03.82.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.71Moderate Buy$27.8833.50% UpsideASNDAscendis Pharma A/S 3.00Buy$220.6725.39% UpsideBBIOBridgeBio Pharma 2.93Moderate Buy$58.8535.28% UpsideIONSIonis Pharmaceuticals 2.78Moderate Buy$58.2539.42% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$87.00119.64% UpsideCurrent Analyst Ratings BreakdownLatest RARE, BBIO, ASND, IONS, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/30/2025BBIOBridgeBio PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $76.006/26/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.006/26/2025ACADACADIA PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$37.006/26/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/26/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/25/2025BBIOBridgeBio PharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $54.006/23/2025ACADACADIA PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.65$0.70 per share29.72$4.40 per share4.75ASNDAscendis Pharma A/S$393.54M27.34N/AN/A($1.88) per share-93.61BBIOBridgeBio Pharma$221.90M37.22N/AN/A($7.71) per share-5.64IONSIonis Pharmaceuticals$705M9.43N/AN/A$3.73 per share11.20RAREUltragenyx Pharmaceutical$560.23M6.68N/AN/A$2.76 per share14.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3715.2427.474.5122.97%17.46%10.75%8/5/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$6.28N/A733.25N/A-93.22%N/A-33.29%9/2/2025 (Estimated)BBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)Latest RARE, BBIO, ASND, IONS, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$263.07 millionN/A5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.882.80ASNDAscendis Pharma A/SN/A1.040.71BBIOBridgeBio PharmaN/A4.574.54IONSIonis Pharmaceuticals2.639.669.62RAREUltragenyx PharmaceuticalN/A2.402.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%IONSIonis Pharmaceuticals93.86%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%ASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma18.20%IONSIonis Pharmaceuticals2.71%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million120.00 millionOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million154.85 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableRARE, BBIO, ASND, IONS, and ACAD HeadlinesRecent News About These CompaniesWCM Investment Management LLC Has $7.65 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)July 3, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 3, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 3, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 6.3% - Should You Buy?July 2, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Below 50 Day Moving Average - What's Next?July 1, 2025 | marketbeat.comRARE's GTX-102 Gets FDA's Breakthrough Status for Angelman SyndromeJune 30, 2025 | zacks.comUltragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drugJune 27, 2025 | au.investing.comUltragenyx Gets FDA Designation to Expedite GTX-102 Drug DevelopmentJune 27, 2025 | marketwatch.comUltragenyx Pharmaceutical Inc. Receives FDA Breakthrough Therapy Designation for GTX-102 to Treat Angelman SyndromeJune 27, 2025 | quiverquant.comQUltragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman SyndromeJune 27, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 2,405 SharesJune 24, 2025 | insidertrades.comFDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding IntentJune 23, 2025 | biospace.comBInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells 2,405 Shares of StockJune 23, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Grants 48,731 Restricted Stock Units to Newly Hired Non-Executive OfficersJune 20, 2025 | quiverquant.comQUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comGuggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)June 20, 2025 | marketbeat.comGAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 17, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Assenagon Asset Management S.A.June 15, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Sells 14,701 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 15, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 3.5% - What's Next?June 12, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by SG Americas Securities LLCJune 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialAs Oil Prices Rebound, These Stocks Could Fuel the Next RallyBy Sarah Horvath | June 9, 2025View As Oil Prices Rebound, These Stocks Could Fuel the Next RallyRARE, BBIO, ASND, IONS, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$20.88 -0.07 (-0.33%) As of 07/7/2025 04:00 PM EasternACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Ascendis Pharma A/S NASDAQ:ASND$175.98 +1.80 (+1.03%) As of 07/7/2025 04:00 PM EasternAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$43.50 -0.49 (-1.11%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$44.28 +0.77 (+1.78%) As of 07/7/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Ionis Pharmaceuticals NASDAQ:IONS$41.78 -1.22 (-2.84%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$41.78 0.00 (0.00%) As of 07/7/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Ultragenyx Pharmaceutical NASDAQ:RARE$39.61 -0.30 (-0.75%) As of 07/7/2025 04:00 PM EasternUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
